A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
- PMID: 20197765
- PMCID: PMC2844041
- DOI: 10.1038/sj.bjc.6605594
A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
Abstract
Background: Given the high burden of cervical cancer in low-income settings, there is a need for a convenient and affordable method for detecting and treating pre-cancerous lesions.
Methods: Samples for comparing the accuracy of cytology, virology and histology were collected. Identification of HPV E6/E7 mRNA was performed using PreTect HPV-Proofer. HPV DNA detection was performed by GP5+/6+ PCR, followed by reverse line blot (RLB) for typing.
Results: A total of 343 women, aged 25-60 years, attending gynaecological polyclinics in DR Congo were included for sample enrolment. The test positivity rate was conventional and liquid-based cytology (LBC) at cutoff ASCUS+ of 6.9 and 6.6%, respectively; PreTect HPV-Proofer of 7.3%; and consensus DNA PCR for 14 HR types of 18.5%. Sixteen cases of CIN2+ lesions were identified. Of these, conventional cytology identified 66.7% with a specificity of 96.2%, LBC identified 73.3% with a specificity of 96.9%, all at cutoff ASCUS+. HR-HPV DNA detected all CIN2+ cases with a specificity of 85.9%, whereas PreTect HPV-Proofer gave a sensitivity of 81.3% and a specificity of 96.6%.
Conclusion: Both HPV detection assays showed a higher sensitivity for CIN2+ than did cytological methods. Detecting E6/E7 mRNA from only a subset of HR HPVs, as is the case with PreTect HPV-Proofer, resulted in a similar specificity to cytology and a significantly higher specificity than consensus HR HPV DNA (P<0.0001).
Figures



Similar articles
-
Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.Int J Cancer. 2005 May 10;114(6):973-6. doi: 10.1002/ijc.20839. Int J Cancer. 2005. PMID: 15645423 Clinical Trial.
-
Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.J Virol Methods. 2009 Jan;155(1):61-6. doi: 10.1016/j.jviromet.2008.09.027. Epub 2008 Nov 13. J Virol Methods. 2009. PMID: 18955086
-
Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.Gynecol Oncol. 2011 Nov;123(2):278-83. doi: 10.1016/j.ygyno.2011.07.024. Epub 2011 Aug 10. Gynecol Oncol. 2011. PMID: 21835440
-
Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.Asian Pac J Cancer Prev. 2015;16(17):7633-40. doi: 10.7314/apjcp.2015.16.17.7633. Asian Pac J Cancer Prev. 2015. PMID: 26625774
-
High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11. Epub 2012 May 2. J Clin Microbiol. 2012. PMID: 22553244 Free PMC article.
Cited by
-
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia.Geburtshilfe Frauenheilkd. 2019 Feb;79(2):148-159. doi: 10.1055/a-0818-5440. Epub 2019 Feb 18. Geburtshilfe Frauenheilkd. 2019. PMID: 30792545 Free PMC article.
-
Towards a "Sample-In, Answer-Out" Point-of-Care Platform for Nucleic Acid Extraction and Amplification: Using an HPV E6/E7 mRNA Model System.J Oncol. 2012;2012:905024. doi: 10.1155/2012/905024. Epub 2011 Dec 22. J Oncol. 2012. PMID: 22235204 Free PMC article.
-
Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis.J Oncol. 2019 Jun 11;2019:6935030. doi: 10.1155/2019/6935030. eCollection 2019. J Oncol. 2019. PMID: 31281360 Free PMC article. Review.
-
Massive single visit cervical pre-cancer and cancer screening in eastern Democratic Republic of Congo.BMC Womens Health. 2019 Mar 4;19(1):43. doi: 10.1186/s12905-019-0737-y. BMC Womens Health. 2019. PMID: 30832697 Free PMC article.
-
Comparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis.Sci Rep. 2022 Jan 7;12(1):94. doi: 10.1038/s41598-021-04201-y. Sci Rep. 2022. PMID: 34997127 Free PMC article.
References
-
- Arbyn M, Hovland S (2006) Test characteristics of multiple cytological and HPV nucleic acid assays to detect high-grade CIN. A study on 343 women from South-Kivu (Democratic Republic of Congo). IPH/EPI-REPORTS 1: 1–60. Brussels
-
- Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, Nouhou H, Sakande B, Wesley R, Somanathan T, Sharma A, Shastri S, Basu P (2008) Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 123: 153–160 - PubMed
-
- Baier T, Hansen-Hagge TE, Gransee R, Crombe A, Schmahl S, Paulus C, Drese KS, Keegan H, Martin C, O’Leary JJ, Furuberg L, Solli L, Grønn P, Falang IM, Karlgård A, Gulliksen A, Karlsen F (2009) Hands-free sample preparation platform for nucleic acid analysis. Lab on a Chip 9: 3399–3405 - PubMed
-
- Bosch FX, de Sanjose S (2003) Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003(31): 3–13. Review - PubMed